1049 related articles for article (PubMed ID: 15780499)
21. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
22. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
24. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.
Menendez JA; Vellon L; Colomer R; Lupu R
Ann Oncol; 2005 Mar; 16(3):359-71. PubMed ID: 15642702
[TBL] [Abstract][Full Text] [Related]
25. Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
Hudelist G; Köstler WJ; Gschwantler-Kaulich D; Czerwenka K; Kubista E; Müller R; Helmy S; Manavi M; Zielinski CC; Singer CF
Eur J Cancer; 2006 Jan; 42(2):186-92. PubMed ID: 16326100
[TBL] [Abstract][Full Text] [Related]
26. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
Kim WE; Serrero G
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.
Narayan M; Wilken JA; Harris LN; Baron AT; Kimbler KD; Maihle NJ
Cancer Res; 2009 Mar; 69(6):2191-4. PubMed ID: 19276389
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
29. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
30. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
Hudelist G; Köstler WJ; Czerwenka K; Kubista E; Attems J; Müller R; Gschwantler-Kaulich D; Manavi M; Huber I; Hoschützky H; Zielinski CC; Singer CF
Int J Cancer; 2006 Mar; 118(5):1126-34. PubMed ID: 16161043
[TBL] [Abstract][Full Text] [Related]
31. Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab.
Voutsas IF; Mahaira LG; Fotopoulou K; Kapranos N; Reclos JG; Gritzapis AD; Papamichail M; Perez SA; Baxevanis CN
Int J Radiat Biol; 2013 May; 89(5):319-25. PubMed ID: 23311575
[TBL] [Abstract][Full Text] [Related]
32. Resistance to trastuzumab: a necessary evil or a temporary challenge?
Cardoso F; Piccart MJ; Durbecq V; Di Leo A
Clin Breast Cancer; 2002 Oct; 3(4):247-57; discussion 258-9. PubMed ID: 12425752
[TBL] [Abstract][Full Text] [Related]
33. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer.
Lesniak D; Xu Y; Deschenes J; Lai R; Thoms J; Murray D; Gosh S; Mackey JR; Sabri S; Abdulkarim B
Cancer Res; 2009 Nov; 69(22):8620-8. PubMed ID: 19887601
[TBL] [Abstract][Full Text] [Related]
34. Opinion on the use of the antitumor drug trastuzumab (Herceptin) in patients with metastatic breast cancer in the county Mecklenburg-Vorpommern.
Hehl EM
Int J Clin Pharmacol Ther; 2001 Nov; 39(11):503-6. PubMed ID: 11727972
[TBL] [Abstract][Full Text] [Related]
35. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
36. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
[TBL] [Abstract][Full Text] [Related]
37. Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase.
Zeng L; Biernacka KM; Holly JM; Jarrett C; Morrison AA; Morgan A; Winters ZE; Foulstone EJ; Shield JP; Perks CM
Endocr Relat Cancer; 2010 Jun; 17(2):539-51. PubMed ID: 20356977
[TBL] [Abstract][Full Text] [Related]
38. Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer.
Menendez JA; Lupu R; Colomer R
Drug News Perspect; 2005; 18(6):375-85. PubMed ID: 16247515
[TBL] [Abstract][Full Text] [Related]
39. Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells.
Bocangel D; Zheng M; Mhashilkar A; Liu Y; Ramesh R; Hunt KK; Chada S
Cancer Gene Ther; 2006 Oct; 13(10):958-68. PubMed ID: 16783343
[TBL] [Abstract][Full Text] [Related]
40. Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2.
Zhang KX; Kim C; Chow E; Chen IS; Jia W; Rennie PS
Breast Cancer Res Treat; 2011 Jan; 125(1):89-97. PubMed ID: 20232140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
